The Zhitong Finance App learned that Goldman Sachs released a research report saying that Hanson Pharmaceuticals (03692.HK) recently published data from the China Phase III study of the B7-H3 antibody-conjugated drug (ADC), showing statistically significant and clinically significant overall survival (OS) benefits in treating recurrent small cell lung cancer (SCLC). The median OS was 18.5 months versus 10.3 months, and the risk ratio (HR) was 0.46. The bank maintained a “buy” rating for Hanson Pharmaceuticals, with a target price of HK$52.7 for 12 months.

The Zhitong Finance App learned that Goldman Sachs released a research report saying that Hanson Pharmaceuticals (03692.HK) recently published data from the China Phase III study of the B7-H3 antibody-conjugated drug (ADC), showing statistically significant and clinically significant overall survival (OS) benefits in treating recurrent small cell lung cancer (SCLC). The median OS was 18.5 months versus 10.3 months, and the risk ratio (HR) was 0.46. The bank maintained a “buy” rating for Hanson Pharmaceuticals, with a 12-month target price of HK$52.7.